Abstract
About this talk
Personalized & precision medicine (PPM) is a model of healthcare services giving healthcare professionals reliable control over morbidity, mortality and disabling rates, and significantly optimize the cost and efficacy of treatment for those who have fallen ill and already diseased, or are still persons-at-risk.
To achieve the goals of value-based healthcare and the implementation of the PPM concept, it is necessary to combine the assets of the newest advances in basic science, OMICS technologies and IT resources with clinical practice.
The goal of PPM is to deliver optimally targeted and timed interventions tailored to an individual’s molecular drivers of disease. In this context, neurological diseases are promisingly suited models for PPM because of the rapidly expanding genetic knowledge base, phenotypic classification, the development of biomarkers and the potential modifying treatments. Advances in disease modeling and methodological design have paved the way for the development of personalized neurology. Biomarkers, biomarker-driven targeting and integration of diagnostics with therapeutics are important for the selection and monitoring of treatments of neurologic disorders, covering: molecular profiling, clinical evaluation, personalized diagnosis, targeted treatment selection, monitoring and adjustment.
The future of PPM-guided neurology lies in multimodal digital data, enabling the principles of PPM in neurological disease diagnostics, treatment, and monitoring at scale, expanding the benefits to everyone. This approach offers a highly accessible, cost-efficient, and non-invasive approach for diagnosing neurological diseases at their clinical and subclinical stages, placing an individual precisely along a disease continuum, and providing the most effective possible canonical and preventive treatment pathways. For instance, multiple sclerosis (MS), Parkinson's disease and amyotrophic lateral sclerosis (ALS), being chronic, autoimmune, demyelinating disease of the central nervous system, are now main targets for implementation of PPM-related resources and search for specific biomarkers of the disease subtypes.
PPM-guided neurology stands at the threshold of a revolutionary transformation with the advent of PPM. By delving into the genetic underpinnings of neurological conditions, we uncover the potential for tailored interventions that promise not only to improve treatment outcomes but also to reshape our understanding of neurological diseases. In this sense, a journey from genomics and related OMICS-driven technologies to personalized therapies is not only transforming neurology-related practice but also offering hope to individuals and families affected by neurological disorders.
By understanding the unique characteristics of a patient's neurological condition, such as genetic predispositions, biomarkers, targets and disease mechanisms, PPM aims to optimize treatment outcomes and improve patient care. Overall, PPM in neurology holds the promise of advancing our understanding of neurological diseases and transforming healthcare by tailoring interventions to the unique needs of each patient. So to fully harvest the unique potential of PPM-guided neurology, new generations of new precision diagnostic, predictive, prognostic, preventive, prophylactic, therapeutic, rehabilitative and digital products will need to be matched with new thinking and new practice on the part of all the participants in the clinical neurology-related practice.
Speaker
About the speaker

